
-
Design Therapeutics NASDAQ:DSGN Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions.
Location: 6005 Hidden Valley Road, CA, 92011, US | Website: www.designtx.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-50.15M
Cash
245.5M
Avg Qtr Burn
-10.78M
Short % of Float
12.87%
Insider Ownership
36.36%
Institutional Own.
59.31%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DT-216 Details Friedreich’s Ataxia | Phase 1 Initiation | |
DT-168 Details Fuchs Endothelial Corneal Dystrophy , Eye disease | Phase 1 Initiation |